Eli Lilly's Investment Strategy Tied to NHS Drug Pricing Reforms

Eli Lilly, the US pharmaceutical company behind the Mounjaro weight-loss drug, has indicated it will resume its investments in the UK contingent upon the government agreeing to increase NHS drug prices and abolish a rebate scheme. Patrik Jonsson, president of Eli Lilly’s international business, expressed optimism about reaching an agreement with UK ministers this summer, which would include discussions on innovative pricing models linked to patient outcomes.

The Guardian

The US pharmaceutical industry has intensified its pressure on the UK government regarding drug pricing. In a significant shift, Labour leader Keir Starmer agreed last year to the first increase in NHS cost-effectiveness thresholds in nearly three decades. This adjustment raised the price the NHS is willing to pay for potentially life-extending drugs from £20,000 to £30,000 per year of life gained to between £25,000 and £35,000. Eli Lilly had previously paused nearly £25 billion in planned investments in the UK, including a laboratory site in London, due to these pricing concerns.

The Guardian

• Eli Lilly: A major US pharmaceutical company focused on innovative treatments, including the Mounjaro weight-loss drug.

The Guardian

• Patrik Jonsson: President of Eli Lilly’s international business, advocating for changes in NHS pricing.

The Guardian

• Keir Starmer: Leader of the Labour Party, who has supported increased NHS drug pricing thresholds.

The Guardian

• Department of Health and Social Care: The UK government body involved in negotiations with Eli Lilly.

The Guardian

Jonsson stated that the current pricing for medicines in the UK has been "far too low for far too long" and emphasized the need for a "well-defined action plan" to guide future investments. He highlighted the potential economic benefits of treating obesity, noting that 2.8 million eligible workers in the UK are absent due to sickness. A spokesperson for the Department of Health and Social Care affirmed the commitment to ensuring access to innovative treatments and the importance of the UK-US pharmaceutical agreement.

The Guardian

While Eli Lilly is eager to explore new pricing agreements, there are concerns regarding the potential impact on NHS access to medications. Critics argue that increasing drug prices could limit access for patients who rely on the NHS for affordable healthcare. The rebate scheme, which requires pharmaceutical companies to pay back a portion of revenue if sales exceed a certain threshold, has also faced scrutiny, with calls for its complete elimination.

The Guardian

• “What we would need to see is actually those goals turning into really a well-defined action plan with interventions and timelines,” — Patrik Jonsson, President, Eli Lilly International

The Guardian

• “ A spokesperson for the Department of Health and Social Care said: “Everyone deserves access to the best and most innovative treatments, and our changes to medicine pricing will make sure thousands of NHS patients gain faster access to new treatments.” — Department of Health and Social Care Spokesperson

The Guardian

Eli Lilly plans to launch a pill version of Mounjaro later this year, and ongoing negotiations with the UK government are expected to shape the future of drug pricing and investment in the UK pharmaceutical sector. The outcome of these discussions will be pivotal in determining the company's commitment to reinvesting in the UK market.

The Guardian